Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 19/20 | 0.83 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17166372 | 1.00 | HCRTR1 (0.83) | HCRTR1HCRTR2ALDH1A1TP53 | |
| SCHEMBL17017366 | 0.91 | HCRTR1 (0.78) | HCRTR1HCRTR2ALDH1A1TP53 | |
| SCHEMBL17028082 | 0.91 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL17007177 | 0.91 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL17021492 | 0.91 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL17017373 | 0.87 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL17166368 | 0.87 | HCRTR1 (0.80) | HCRTR1HCRTR2 | |
| SCHEMBL16666165 | 0.85 | HCRTR1 (0.67) | HCRTR1HCRTR2ALDH1A1TP53 | |
| SCHEMBL22131250 | 0.83 | HCRTR1 (0.65) | HCRTR1HCRTR2ALDH1A1TP53 | |
| SCHEMBL17017307 | 0.83 | HCRTR1 (0.65) | HCRTR1HCRTR2ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885ALDH1A1 552/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885ALDH1A1 552/4885 |
| US-20150232460-A1 | NOVEL COMPOUNDS | CNKSR1, RDX, RB1 | HCRTR1 631/4885HCRTR2 1815/4885ALDH1A1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.